Press coverage about HTG Molecular Diagnostics (NASDAQ:HTGM) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. HTG Molecular Diagnostics earned a news impact score of 0.09 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 45.167052528066 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Critical Review: Horiba (HRIBF) vs. HTG Molecular Diagnostics (HTGM) (americanbankingnews.com)
- HTG Molecular Diagnostics Inc (HTGM) Expected to Post Quarterly Sales of $5.19 Million (americanbankingnews.com)
- Comparing Aethlon Medical (AEMD) & HTG Molecular Diagnostics (HTGM) (americanbankingnews.com)
- HTG Molecular Announces Amendment to Second Statement of Work with QIAGEN Manchester Limited (finance.yahoo.com)
- -$0.18 EPS Expected for HTG Molecular Diagnostics Inc (HTGM) This Quarter (americanbankingnews.com)
A number of research firms have recently commented on HTGM. ValuEngine downgraded HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a report on Wednesday, June 27th. HC Wainwright set a $7.00 price target on HTG Molecular Diagnostics and gave the stock a “buy” rating in a research note on Monday, July 2nd. Finally, Zacks Investment Research downgraded HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday, June 20th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $6.17.
Shares of HTGM traded down $0.03 during mid-day trading on Friday, hitting $3.58. The company’s stock had a trading volume of 429,203 shares, compared to its average volume of 401,623. The company has a debt-to-equity ratio of 0.31, a current ratio of 9.80 and a quick ratio of 9.59. The stock has a market capitalization of $102.57 million, a P/E ratio of -2.00 and a beta of 1.46. HTG Molecular Diagnostics has a 1-year low of $1.59 and a 1-year high of $5.83.
HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its quarterly earnings results on Thursday, August 9th. The medical research company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05. The business had revenue of $4.91 million during the quarter, compared to analysts’ expectations of $5.30 million. HTG Molecular Diagnostics had a negative return on equity of 215.21% and a negative net margin of 81.10%. research analysts anticipate that HTG Molecular Diagnostics will post -0.71 EPS for the current year.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
Featured Story: Growth Stocks
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.